Central Cancer Registry Reporting Content IG
2.0.0-ballot - STU 2 -Ballot United States of America flag

Central Cancer Registry Reporting Content IG, published by HL7 International / Public Health. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-central-cancer-registry-reporting-ig/ and changes regularly. See the Directory of published versions

: Cancer Related Medication Administration - Example - XML Representation

Page standards status: Informative

Raw xml | Download


<MedicationAdministration xmlns="http://hl7.org/fhir">
  <id value="cancer-med-admin-docetaxel-example"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Profile: </b> <a href="https://hl7.org/fhir/us/mcode/StructureDefinition-mcode-cancer-related-medication-administration.html">mCODE Cancer Related Medication Administration</a></p><p><b>status:</b> completed</p><p><b>category:</b> Outpatient</p><p><b>medication:</b> rxnorm 72962 docetaxel</p><p><b>subject:</b> <a href="Patient-example.html">Patient-example: Amy Shaw</a></p><p><b>start date:</b> 2023-04-10</p><p><b>Performer:</b> Joseph Nichols</p><p><b>reasonReference:</b> Condition-primary-cancer-condition-breast</p><p><b>authoredOn:</b> 2023-04-10</p><p><b>note:</b> Chemotherapy regimen of docetaxel, carboplatin, adriamycin, cyclophosphamide, and paclitaxel administered by continuous infusion. Patient tolerated infusion without side effects.</p><p><b>Route:</b> SNOMED 47625008 Intravenous route (qualifier value)</p></div>
  </text>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/medication-admin-category"/>
      <code value="outpatient"/>
    </coding>
  </category>
  <medicationCodeableConcept>
    <coding>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <code value="72962"/>
      <display value="docetaxel"/>
    </coding>
  </medicationCodeableConcept>
  <subject>🔗 
    <reference value="Patient/example"/>
  </subject>
  <effectiveDateTime value="2023-04-10"/>
  <performer>
    <actor>🔗 
      <reference value="Practitioner/1"/>
    </actor>
  </performer>
  <reasonCode>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="408643008"/>
      <display value="Infiltrating duct carcinoma of breast (disorder)"/>
    </coding>
  </reasonCode>
  <reasonReference>🔗 
    <reference value="Condition/primary-cancer-condition-breast"/>
  </reasonReference>
  <note>
    <authorReference>🔗 
      <reference value="Practitioner/1"/>
    </authorReference>
    <time value="2023-04-10"/>
    <text
          value="docetaxel administered by continuous infusion. Patient tolerated infusion without side effects."/>
  </note>
  <dosage>
    <route>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="47625008"/>
        <display value="Intravenous route (qualifier value)"/>
      </coding>
    </route>
    <dose>
      <value value="60"/>
      <unit value="mg"/>
      <system value="http://unitsofmeasure.org"/>
      <code value="mg"/>
    </dose>
  </dosage>
</MedicationAdministration>